Cardinal Health's CFO Aaron Alt sold 42,000 shares worth $9.9 million on August 18, reducing his direct holdings to 20,495 shares. The sale occurred after the stock surged 57% over the past year. Despite the insider sale, the company maintains strong guidance with fiscal 2027 EPS projected at $12.40-$12.60 (13-15% growth), planned capital expenditures of $700 million, and at least $1 billion in share repurchases expected.

Stephen M. Mason, CEO of Cardinal Health's GMPD Segment, sold 35,000 shares worth $8.3 million on August 18, reducing his direct holdings by 29%. While the stock has gained 57% over the past year, the Medical segment continues to face challenges with declining revenue and profit margins, with fiscal 2027 projections ranging from $200-220 million depending on geopolitical factors.

Deborah Weitzman, CEO of Cardinal Health's PSS Segment, sold 7,354 shares for ~$1.7 million on August 18, 2026, but still increased her total stake by 47% after receiving performance units. Despite the sale, her direct holdings grew to 77,901 shares valued at $18.31 million. The Pharmaceutical and Specialty Solutions segment she leads showed strong performance with 6% revenue growth and 21% profit growth in Q4, with specialty business growing over 25% in fiscal 2026.

Cardinal Health's CIO Michelle Greene sold 11,650 shares worth $2.7 million at a weighted average price of $235.72, reducing her direct stake by roughly 16%. While the sale follows strong stock appreciation, the article notes that Greene sold more aggressively than other executives like the CEO and legal officer. The transaction occurred amid the company's August award cycle and comes as Cardinal Health guides lower adjusted free cash flow for fiscal 2027 despite record capital expenditures in technology and automation.

The global gauze bandage rolls market is valued at USD 1.96 billion in 2025 and is projected to reach USD 3.19 billion by 2035, growing at a CAGR of 4.97%. Growth is driven by rising surgical procedures, aging populations, chronic wound management, and technological advancements in antimicrobial and bioactive gauze products. Key market segments include cotton gauze (largest share), surgical wounds (dominant application), and hospitals (primary end-user), with Asia Pacific expected to show the fastest growth.

The global surgical masks market is projected to grow from USD 3.95 billion in 2024 to USD 6.76 billion by 2034 at a CAGR of 5.5%. Growth is driven by rising healthcare applications, infection control awareness, and surgical interventions, though environmental concerns about disposal and competition from alternative respirators pose challenges. Europe is expected to lead the market, while basic surgical masks will dominate the product segment.

The global pregnancy detection kits market is projected to grow from USD 1.91 billion in 2025 to USD 2.69 billion by 2031, with a CAGR of 5.87%. Growth is driven by technological advancements enabling earlier detection, rising infertility rates, and increasing adoption of digital integration and e-commerce distribution. However, the market faces challenges from accuracy concerns and user error risks that erode consumer trust.

Cardinal Health's Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, payable on July 15, 2026 to shareholders of record as of July 1, 2026. The dividend will be paid out of the company's capital surplus.

The Dow Jones surged 1.5% driven by industrial and healthcare stocks, while mega-cap tech faced pressure from concerns over AI capital spending. Meta and Microsoft declined on capex worries, but Alphabet gained on enterprise AI wins. Industrials like Caterpillar, Quanta Services, and Carrier rallied on data-center infrastructure demand. The S&P 500 gained 0.5% while the Nasdaq 100 remained flat.

Cardinal Health reported mixed Q3 2026 earnings with an EPS beat of $3.17 vs. $2.79 consensus, but revenue missed at $60.94B vs. $61.70B expected. Despite raising full-year guidance and reporting strong operational performance, the stock fell 8.23% to $186.12, likely due to the revenue miss and flat performance in the medical products segment.

The global radiopharmaceuticals market is projected to grow from USD 8.28 billion in 2026 to USD 15.21 billion by 2035, driven by rising cancer and cardiovascular disease incidence. North America dominates with 43.95% market share, while Asia-Pacific is expected to register the fastest growth. Therapeutic radiopharmaceuticals and Technetium-99m lead their respective segments, with hospitals and clinics as the primary end users.

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.